Tokyo-based Teijin Pharma plans to launch gout drug Uloric (febuxostat) in European markets this fall after a March launch in the U.S. through licensee Takeda Pharmaceutical North America. The company also plans a NDA submission in Japan aiming for a 2011 domestic market launch. Billed as the first novel treatment for hyperuricemia in patients with gout in more than 40 years, the drug is expected to grow to achieve ¥100 billion in annual sales. (Click here for more - Japanese language
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.
Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.
Recent moves in the industry include C-suite changes at Atalanta Therapeutics and Climb Bio, plus seven companies get new CMOs.
